Allogeneic chimeric antigen receptor-T cells with CRISPR-disrupted programmed death-1 checkpoint exhibit enhanced functional fitness-Reference-Cited by-同舟云学术

Allogeneic chimeric antigen receptor-T cells with CRISPR-disrupted programmed death-1 checkpoint exhibit enhanced functional fitness

Published:2023-07 Issue:7 Volume:25 Page:750-762
ISSN:1465-3249
Container-title:Cytotherapy
language:en
Short-container-title:Cytotherapy

Author:

Lau Elaine,Kwong George,Fowler Tristan W.,Sun Bee-Chun,Donohoue Paul D.^ORCID,Davis Ryan T.^ORCID,Bryan Mara,McCawley Shannon^ORCID,Clarke Starlynn C.,Williams Carolyn,Banh Lynda^ORCID,Irby Matthew,Edwards Leslie,Storlie Meghan,Kohrs Bryan^ORCID,Lilley Graham W.J.,Smith Stephen C.,Gradia Scott^ORCID,Fuller Chris K.^ORCID,Skoble Justin^ORCID,Garner Elizabeth^ORCID,van Overbeek Megan,Kanner Steven B.^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Transplantation,Cell Biology,Genetics (clinical),Oncology,Immunology,Immunology and Allergy

Reference73 articles.

1. Chimeric antigen receptor therapy;June;N Engl J Med,2018

2. Emerging cellular therapies for cancer;Guedan;Annu Rev Immunol,2019

3. Engineered T cells: CAR T cell therapy and beyond;Johnson;Curr Oncol Rep,2022

4. Engineered cellular immunotherapies in cancer and beyond;Finck;Nat Med,2022

5. Real-world experiences of CAR T cell therapy for large B cell lymphoma: how similar are they to the prospective studies?;Tang;J Immunother Precis Oncol,2021

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revolutionizing Cancer Treatments through Stem Cell-Derived CAR T Cells for Immunotherapy: Opening New Horizons for the Future of Oncology;Cells;2024-09-10

2. Boosting CAR-T cell therapy with CRISPR technology;hLife;2024-08

3. CRISPR technology in human diseases;MedComm;2024-07-29

4. CAR-T cell expansion platforms yield distinct T cell differentiation states;Cytotherapy;2024-07

5. Prospects and challenges of CAR-T cell therapy combined with ICIs;Frontiers in Oncology;2024-03-20